Novo Nordisk Prioritizes Clinical Depth Over Price Competitiveness to Compete with Generic Alternatives

Novo Nordisk Defends Semaglutide Market Share in India

Key Figures:

• Rs 445 crore: Semaglutide sales for the year ended February 2026
• 40+: Number of Indian manufacturers offering generic semaglutide
• 50+: Number of generic semaglutide brands available in India
• 90%: Discount offered by Natco Pharma on multi-dose vials compared to Novo Nordisk's innovator therapies
• Rs 8,800-Rs 11,175: Price range for Novo Nordisk's pen devices for Ozempic
• Rs 16,400: Price for Novo Nordisk's pen devices for Wegovy
• 37%: Reduction in injectable semaglutide prices by Novo Nordisk in December

Market Overview

Read also: Oshea Herbals Aims for Rs 650 Crore Revenue Amidst Expansion Efforts

The patent expiry of semaglutide injections, sold by Novo Nordisk under brand names Ozempic and Wegovy, has led to a fierce price war in India. More than 40 Indian manufacturers have launched over 50 generic brands, significantly slashing prices across formats. Natco Pharma has priced its multi-dose vials at Rs 1,290 a month, a 90% discount to Novo's innovator therapies.

Novo Nordisk's Strategy

To maintain its market share, Novo Nordisk India managing director Vikrant Shrotriya emphasized the importance of localized pricing, robust logistics, and partnerships. The company has partnered with Abbott India and Emcure to strengthen distribution in tier 2 and tier 3 regions. These alliances aim to keep Novo in the premium segment of the market, despite the intense competition.

Clinical Evidence and Partnerships

Read also: Suzlon to Expand Business Scope Beyond Wind Energy, Invests Rs 500 Crore in New Subsidiary This Fiscal Year

Novo Nordisk is relying on its decade-long clinical data, state-of-the-art manufacturing technology, and high safety standards to preserve its clinical authority in the market. The company has also partnered with Indian players to strengthen distribution and marketing reach, especially in tier 2 and tier 3 regions.

Industry Insights

Industry experts believe that Novo Nordisk will not engage in indiscriminate discounting, as it may lead to erosion of volumes. Generics may face challenges in gaining market share, despite their low prices, due to the complexity of GLP-1 medications and the need for high manufacturing standards.